When the drug Sovaldi (sofosbuvir) was first introduced in September 2014, it not only marked a sea change in how hepatitis C infection was treated,1 it made obsolete earlier generation medications which were nowhere near as effective. Within months of Sovaldi's arrival, such hepatitis C mainstays as Incivek (telaprevir) and Victrelis (boceprevir) were quickly yanked from the market, never to be seen again. Following fast on Sovaldi's heels was the introduction of five additional drug formulations able to treat an ever-widening range of hepatitis C genotypes. Buy Hep C Drugs Online These newer drugs not only offered fewer side effects but also reduced the course of therapy by as much as three months. With cure rates now exceeding 95 percent in many cases,2 the only real challenge is how to expand access to the 130 to 150 million people chronically infected with hepatitis C worldwide. As treatment durations decreased and cure rates climbed, less competitive direct-acting antivirals quickly lost popularity and were voluntarily withdrawn from the marketplace. These included the drug Olysio (simeprevir), which was pulled in May 2018, and the combination drugs Technivie (ombitasvir/paritaprevir/ritonavir) and Viekira Pak (ombitasvir/paritaprevir/ritonavir plus dasabuvir), both of which were discontinuation on January 1, 2019. The remaining mainstays of hepatitis C treatment are listed by the order of their FDA approval. You can buy Generic Hepatitis C Drugs Online in Indian Pharmacy Medixo Centre GET 100% Low price Order Now: Hepcinat Lp // Myhep All // Velpanat // Ledifos // Dacihep // Daclahep // Hepcinat // Hepcinat Plus // Ledikast // Ledihep // Mydekla // Myhep // Myhep Dvir // Myhep Lvir // Natdac // Resof // Resof L // Resof Total // Sofovir // Sovihep // Sovihep V // Velakast // Velasof // Revolade 50 mg // Revolade 25 mg //
Button Text